Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study

Data de publicació: 01/04/2021

Autors de IIS La Fe

Miguel Salavert Lletí

Autor

Autors aliens a IIS La Fe

Bouza, E
Cobo, J
Rodriguez-Hernandez, MJ
Horcajada, JP
Iribarren, JA
Obi, E
Lozano, V
Maratia, S
Cuesta, M
Uria, E
Limon, E

Grups d'Investigació

Infección Grave

Investigador Principal

María Ángeles Tormo Mas

Abstract

Introduction. Clostridioides difficile infection (CDI) is associated with increased hospital stays and mortality and a high likelihood of rehospitalization, leading to increased health resource use and costs. The objective was to estimate the economic burden of recurrent CDI (rCDI). Material and methods. Observational, retrospective study carried out in six hospitals. Adults aged >= 18 years with >= 1 confirmed diagnosis (primary or secondary) of rCDI between January 2010 and May 2018 were included. rCDI-related resource use included days of hospital stay (emergency room, ward, isolation and ICU), tests and treatments. For patients with primary diagnosis of rCDI, the complete hospital stay was attributed to rCDI. When diagnosis of rCDI was secondary, hospital stay attributed to rCDI was estimated using 1:1 propensity score matching as the difference in hospital stay compared to controls. Controls were hospitalizations without CDI recorded in the Spanish National Hospital Discharge Database. The cost was calculated by multiplying the natural resource units by the unit cost. Costs (euros) were updated to 2019. Results. We included 282 rCDI episodes (188 as primary diagnosis): 66.31% of patients were aged >= 65 years and 57.80% were female. The mean hospital stay (SD) was 17.18 (23.27) days: 86.17% of rCDI episodes were isolated for a mean (SD) of 10.30 (9.97) days. The total mean cost (95%-CI) per episode was (sic)10,877 (9,499-12,777), of which the hospital stay accounted for 92.56%. Conclusions. There is high cost and resource use associated with rCDI, highlighting the importance of preventing rCDI to the Spanish National Health System.

Dades de la publicació

ISSN/ISSNe:: 0214-3429, 1988-9518
Tipus:: Article
Pàgines:: 126-135
DOI:: 10.37201/req/135.2020
PubMed:: 33618513
Factor d'Impacte:: 0,440 SCImago ℠
Quartil:: Q3 SCImago ℠

Documents

No hi ha documents

Mètriques

Filiacions

Bouza, E:: Hosp Gen Univ Gregorio Maranon, Madrid, Spain
Cobo, J:: Hosp Univ Ramon y Cajal, Madrid, Spain
Rodriguez-Hernandez, MJ:: Hosp Virgen del Rocio, Seville, Spain
Salavert, M:: Hosp Univ & Politecn La Fe, Valencia, Spain
Horcajada, JP:: Hosp del Mar IMIM, Barcelona, Spain
Iribarren, JA:: Hosp Univ Donostia, San Sebastian, Spain
Obi, E:: Merck & Co Inc, Kenilworth, NJ USA
Lozano, V:: Merck Sharp & Dohme Ltd, Calle Josefa Valcarcel 38, Madrid 28027, Spain
Maratia, S:: Merck Sharp & Dohme Ltd, Calle Josefa Valcarcel 38, Madrid 28027, Spain
Cuesta, M:: Oblikue Consulting SL, Barcelona, Spain
Uria, E:: Oblikue Consulting SL, Barcelona, Spain
Limon, E:: Univ Barcelona, VINCat Coordinator Ctr, Catalan Hlth Dept, Barcelona, Spain